Micronized Lipid Particles for Tear Film and Suspension Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective treatments and delivery systems for dry eye syndrome, particularly those that address tear film instability and lipid layer insufficiency, which are common causes of dry eye conditions.
Innovation Solution
The development of micronized lipid particles, specifically ether lipids like sn-1-O-eicosanyl-sn-2-palmitoyl-glycerol and its isomers, formulated as drug delivery vehicles with a size of less than 100 microns, which are stable in aqueous suspension and provide a therapeutic lipid layer to enhance tear film stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lipid particles are micronized to less than 100 microns for improved tear film stability, then tear film stability is improved, but particle suspension stability becomes more difficult to maintain
Solution Approach 1:
The patent applies parameter changes by optimizing the particle size distribution of micronized lipid particles (maintaining average size less than 100 microns while controlling size distribution) and adjusting suspension medium properties (pH, ionic strength, surfactant concentration) to maintain both tear film stability and suspension stability simultaneously
Solution Approach 2:
The patent uses composite materials by formulating the lipid particle suspension with a combination of lipid particles, aqueous vehicle, surfactants, and stabilizing agents to achieve both improved tear film stability and maintained suspension stability
2Ease of operation
If lipid particles are micronized to less than 100 microns for better ocular penetration, then ocular comfort is enhanced, but manufacturing precision requirements increase
Solution Approach 1:
The patent applies preliminary action by pre-micronizing lipid particles to the target size range (<100 microns) before final formulation, and pre-testing the suspension stability under various conditions to optimize the final product without requiring excessive precision during final manufacturing
Solution Approach 2:
The patent uses parameter changes by controlling particle size distribution parameters (average size, size range) and formulation parameters (surfactant concentration, pH) to achieve both ocular comfort and manageable manufacturing precision requirements
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The micronized lipid particles effectively improve tear film stability, reducing symptoms of dry eye by prolonging tear breakup time and enhancing ocular comfort, as demonstrated in clinical trials.
Implementation Method 1
solid non-polar lipid particles comprising an active lipid agent and having an average particle size of less than 50 microns stably suspended in a buffered aqueous vehicle suitable for topical administration
Data Source
AI summary
The present invention relates to drug delivery vehicles comprising micronized particles that include an active lipid agent, and in particular to micronized lipid particles that comprise an ether lipid such as sn-1-O-eicosanyl-sn-2-palmitoyl-glycerol and its isomers.